韓劇電影你都看哪一部呢？論文書籍站
臺北醫學大學 國際醫學研究碩士學位學程 CHEN, CHIEH-FENG所指導 HOANG DINH KHANH的 Oral aspirin for preventing colorectal adenoma recurrence: a systematic review and network meta-analysis of randomized controlled trials （2021），提出MSI MP241 PTT關鍵因素是什麼，來自於Aspirin/acetylsalicylic acid、chemoprevention、colorectal adenomas、randomized controlled trials、network meta-analysis。
而第二篇論文長庚大學 臨床醫學研究所 余兆松所指導 蔣昇甫的 運用體學研究策略發現血清蛋白「骨髓基質抗原二」與「腺瘤型大腸瘜肉基因」組織變異可作為大腸直腸癌的預後因子 （2020），提出因為有 大腸直腸癌、骨髓基質抗原二、腺瘤型大腸瘜肉基因、預後因子、分泌蛋白體、次世代定序的重點而找出了 MSI MP241 PTT的解答。
Oral aspirin for preventing colorectal adenoma recurrence: a systematic review and network meta-analysis of randomized controlled trials
為了解決MSI MP241 PTT 的問題，作者HOANG DINH KHANH 這樣論述：
Objective To evaluate the preventive effect of aspirin on polypoid lesions in the colorectum and recommend the optimal dose for clinical useDesign Systematic review and network meta-analysisData sources A multilingual, comprehensive source of aspirin clinical trials for colorectal adenoma preventio
n updated to December 31st, 2021Study selection Only randomized controlled trial studies, consisting of participants randomly assigned to receive aspirin (high dose or low dose) or placebo, were included.Methods Pairwise meta-analysis, meta-regression, trial sequential analysis, and network meta-ana
lysis were done after all eligible studies inclusion. ROB 2.0 tool was used for assess risk of bias assessments in included studies, and confidence in the results of network meta-analysis was evaluated by using CINeMA approach.Results The network meta-analysis included eight randomized controlled tr
ials (nine reports) – four of aspirin (low dose or high dose) alone (n = 1,820 participants), four of aspirin in combination with one another medication including folic acid (n = 421), resistant starch (n = 342), eicosapentaenoic acid (n = 326) and mesalazine (n = 102), all compared to placebo. For
pairwise meta-analysis, based on data from seven trials aspirin (any dose) substantially reduced the colorectal adenoma recurrence in participants with or without adenoma-related genetic syndromes (risk ratio 0.86, 95% confidence interval: 0.75 to 0.99). Meta-regression indicated that there was no
correlation between aspirin dose and colorectal adenoma recurrence (p-value = 0.58 for linear model, p-value = 0.76 for non-linear model). For network meta-analysis, low-dose aspirin was still more protective than both high-dose aspirin and placebo, with risk ratio and 95% confidence interval being
0.76 (95% confidence interval 0.58 – 0.99), 0.7 (95% confidence interval 0.54 – 0.91), respectively. Synchronously, low-dose aspirin was ranked the best treatment among the network of low-dose, high-dose aspirin, and placebo (P-score = 0.99). Thus, LDA was the optimal treatment relative to HDA and p
lacebo (P-score = 0.99) with moderate certainty of evidence due to some concerns in heterogeneity. But for trial sequential analysis, low-dose aspirin only showed its efficacy over placebo when the number of included participants exceeded the optimal information size, this was not the case for HDA.C
onclusions Low-dose aspirin has statistically significant efficacy in colorectal adenoma prevention, especially for long-term use but its efficacy over high-dose aspirin is uncertain based on available data which needs more trials to confirm.
運用體學研究策略發現血清蛋白「骨髓基質抗原二」與「腺瘤型大腸瘜肉基因」組織變異可作為大腸直腸癌的預後因子
為了解決MSI MP241 PTT 的問題，作者蔣昇甫 這樣論述：
大腸直腸癌（CRC）在全球癌症的發病率中位居第三位，而死亡率上則排名第二位。近幾十年來在台灣，大腸直腸癌早已成為一個重大的健康議題。但台灣的大腸癌第四期的比例仍偏高，而大腸癌診斷的主要工具—大腸鏡檢查及血液中的癌胚胎抗原（CEA），用於早期偵測大腸癌仍有其限制，一方面是CEA缺乏對於早期大腸癌的準確性，另一方面，大腸鏡檢查仍具有腸穿孔、腸出血的風險，故發展大腸癌腫瘤標誌仍是當務之急。長庚大學研究團隊先前使用來自11種癌症的23種人類癌細胞株，建立了癌細胞分泌蛋白體(secretome)資料庫，其中包含109種大腸癌細胞株所特有的分泌蛋白質。根據它們的優先次序，本論文透過西方墨點法和免疫組織化
學法測試了數個蛋白質（TACSTD2 / TROP2，TM9SF2，NGFR，FGF9和BST2）。其中，我們發現TROP2和BST2在大腸癌病人組顯著上升。但是在擴大的臨床驗證驗證中，僅BST2被發現在大腸癌病人和健康對照者的血液含量顯著不同，大腸癌病人的血液中BST2濃度顯著增加（2.35±0.13 ng / mL比1.04±0.03 ng / mL，p